Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
The investigator assesses the efficacy and safety of alpelisib and capecitabine in patients
with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies.